Skip to main content
Premium Trial:

Request an Annual Quote

Slight Revenue Uptick for Amersham Biosciences Discovery Unit

NEW YORK, April 30 - Amersham PLC had sales of ₤381 million ($608 million) for the first quarter of 2003, up 6 percent compared to the year-ago quarter, the company said today.

 

Amersham Biosciences, the Piscataway, NJ-based unit of London-based Amersham, has sales of ₤157 million ($251 million) for the quarter, including sales of ₤95 million ($152 million) for its restructured discovery systems division. The unit's sales grew by 2 percent, excluding discontinued product sales of ₤7 million ($11 million), with growth in proteomics and bioassays overcoming declines in genomics product lines, the company added.

 

In February, the company announced a restructuring in its discovery systems group, firing 400 workers, and reshuffling management in an effort to bring the unit to profitability by 2004.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.